Articles Related to Rituximab
Treating Refractory Myasthenia Gravis with Rituximab – Case Report
Myasthenia gravis is an autoimmune disease characterized by motor plaque dysfunction due to antibodies against post-synaptic membrane proteins. Myasthenic symptoms classically wax and wane and are more intense at the end of the day, although they may be constant in severe pictures. Almost every patient have eyelid ptosis and double vision, and the majority of them also have proximal muscle weakness. Reversible cholinesterase inhibitors are the first-line treatment, but patients who do not achieve symptom control should receive immunosuppressive therapy, whose options include azathioprine, cyclosporine, mycophenolate, intravenous immunoglobulin and thymectomy, with different profiles of efficacy, safety and tolerability.
Vasculitis Associated with Chronic Lymphocytic Leukemia
A patient is present who has chronic lymphocytic leukemia (CLL) and developed a vasculitis involving the skin and large vessels along with immune complex mediated glomerulosclerosis. Both vasculitis and immune complex nephritis are rare manifestations of CLL.
Editorial Board Members Related to Rituximab
BRUCE D CHESON
Professor of Medicine
Division of Hematology and Oncology
Georgetown University Hospital
United States
Division of Hematology and Oncology
Georgetown University Hospital
United States